• In 2022, revenue fell 24% YoY to $7.1M, but beat our estimate by 8%. Revenue declined as the company discontinued in-house manufacturing, and production for third parties. As a result, this company was able to lower G&A expenses by 35% YoY, and improve EBITDA from -$14M to -$9M vs our estimate of -$11M.
          • This report is currently available to premium subscribers – Free subscribers will gain access on Mar 15th, 2022 Join as a FREE member and get our research report delivered straight to your inbox, with a seven-day delay

Visit Elixinol Wellness Limited page for more research, discussion boards and to like, and share.

Download Analyst Report :